Barrier Function and Production of Inflammatory Cytokines in the Rectal Mucosa in Patients With Septic Shock
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00378586|
Recruitment Status : Unknown
Verified June 2009 by Herlev Hospital.
Recruitment status was: Not yet recruiting
First Posted : September 20, 2006
Last Update Posted : June 23, 2009
Life-threatening infection impairs bloodflow to the gut, thereby causing less delivery of oxygen. This leads to increased formation of different inflammatory and infectious markers.
The investigators hypothesize, therefore, that there is a significant difference in the concentrations of inflammatory and infectious markers in the rectal mucosa between patients with septic shock and healthy controls.
|Condition or disease||Intervention/treatment|
|Septic Shock||Procedure: Rectal biopsy Procedure: Measurement of inflammatory markers in the rectal mucosa Procedure: Measurement of rectal lactic acid|
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Barrier Function and Production of Inflammatory Cytokines in the Rectal Mucosa in Patients With Septic Shock|
|Study Start Date :||January 2010|
- Procedure: Rectal biopsy
- Procedure: Measurement of inflammatory markers in the rectal mucosa
- Procedure: Measurement of rectal lactic acid
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00378586
|Contact: Michael Ibsen, MD||+ 45 45 35 94 firstname.lastname@example.org|
|Contact: Anders Perner, MD, PhD||+ 45 45 35 41 email@example.com|
|Dept. of Intensive Care 4131||Not yet recruiting|
|Copenhagen, Denmark, DK-2100|
|Contact: Michael Ibsen, MD +45 45 35 94 18 firstname.lastname@example.org|
|Principal Investigator:||Michael Ibsen, MD||Dept. of Intensive Care 4131, Rigshospitalet, Copenhagen, Denmark|